Pharming Group Future Growth
Future criteria checks 4/6
Pharming Group is forecast to grow earnings and revenue by 73.2% and 9.7% per annum respectively. EPS is expected to grow by 72.1% per annum. Return on equity is forecast to be 10.9% in 3 years.
Key information
73.2%
Earnings growth rate
72.1%
EPS growth rate
| Biotechs earnings growth | 37.4% |
| Revenue growth rate | 9.7% |
| Future return on equity | 10.9% |
| Analyst coverage | Low |
| Last updated | 04 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 360 | 19 | 19 | 26 | 4 |
| 12/31/2025 | 320 | 1 | 5 | 11 | 4 |
| 12/31/2024 | 289 | -10 | 2 | 7 | 4 |
| 9/30/2024 | 286 | -18 | 0 | 0 | N/A |
| 6/30/2024 | 278 | -13 | -6 | -6 | N/A |
| 3/31/2024 | 258 | -11 | 18 | -2 | N/A |
| 12/31/2023 | 245 | -11 | 3 | -17 | N/A |
| 9/30/2023 | 219 | -22 | -4 | -24 | N/A |
| 6/30/2023 | 206 | -16 | 5 | -15 | N/A |
| 3/31/2023 | 202 | -2 | -3 | -1 | N/A |
| 12/31/2022 | 206 | 14 | 20 | 22 | N/A |
| 9/30/2022 | 204 | 30 | 25 | 33 | N/A |
| 6/30/2022 | 202 | 21 | 15 | 26 | N/A |
| 3/31/2022 | 202 | 11 | 17 | 31 | N/A |
| 12/31/2021 | 199 | 16 | 21 | 38 | N/A |
| 9/30/2021 | 200 | 22 | 29 | 43 | N/A |
| 6/30/2021 | 200 | 31 | 40 | 52 | N/A |
| 3/31/2021 | 202 | 37 | 59 | 70 | N/A |
| 12/31/2020 | 212 | 38 | 68 | 84 | N/A |
| 9/30/2020 | 212 | 44 | 70 | 85 | N/A |
| 6/30/2020 | 202 | 46 | 59 | 93 | N/A |
| 3/31/2020 | 202 | 42 | 53 | 84 | N/A |
| 1/1/2020 | 189 | 41 | 49 | 74 | N/A |
| 9/30/2019 | 175 | 38 | 48 | 70 | N/A |
| 6/30/2019 | 175 | 34 | 59 | 63 | N/A |
| 3/31/2019 | 158 | 29 | 54 | 57 | N/A |
| 12/31/2018 | 155 | 29 | 42 | 46 | N/A |
| 9/30/2018 | 152 | -29 | 57 | 63 | N/A |
| 6/30/2018 | 138 | -44 | N/A | 61 | N/A |
| 3/31/2018 | 128 | -80 | N/A | 52 | N/A |
| 12/31/2017 | 108 | -91 | N/A | 46 | N/A |
| 9/30/2017 | 76 | -53 | N/A | 14 | N/A |
| 6/30/2017 | 47 | -47 | N/A | -6 | N/A |
| 3/31/2017 | 31 | -21 | N/A | -13 | N/A |
| 12/31/2016 | 17 | -18 | N/A | -11 | N/A |
| 9/30/2016 | 12 | -16 | N/A | -18 | N/A |
| 6/30/2016 | 12 | -15 | N/A | -18 | N/A |
| 3/31/2016 | 13 | -14 | N/A | -18 | N/A |
| 12/31/2015 | 12 | -11 | N/A | -19 | N/A |
| 9/30/2015 | 29 | 8 | N/A | -3 | N/A |
| 6/30/2015 | 27 | 9 | N/A | -1 | N/A |
| 3/31/2015 | 23 | 10 | N/A | -3 | N/A |
| 12/31/2014 | 26 | -7 | N/A | -3 | N/A |
| 9/30/2014 | 6 | -29 | N/A | -19 | N/A |
| 6/30/2014 | 6 | -35 | N/A | -16 | N/A |
| 3/31/2014 | 11 | -35 | N/A | -14 | N/A |
| 12/31/2013 | 9 | -21 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0QCO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Earnings vs Market: 0QCO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0QCO is expected to become profitable in the next 3 years.
Revenue vs Market: 0QCO's revenue (9.7% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: 0QCO's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0QCO's Return on Equity is forecast to be low in 3 years time (10.9%).